Of these two, itraconazole has most promise as a pharmaceutical invention targeting NPC1, since it is already included in several clinical trials as an anti-cancer drug due to its ability to inhibit hedgehog pathway as well as due to its various anticancer activities including its ability to target multidrug resistance via ABC transporters [120]. Here, ABCG2 is linked to cancer.